Patents Assigned to Centre Régional de Lutte Contre le Cancer
  • Mcl-1 modulating compounds for cancer treatment
    Patent number: 10307410
    Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 4, 2019
    Assignees: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE, UNIVERSITE DE CAEN BASSE-NORMANDIE, INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Inventors: Laurent Poulain, Anne-Sophie Voisin-Chiret, Jana Sopkova-de Oliveira Santos, Ronan Bureau, Grégory Burzicki, Marcella De Giorgi, Serge Perato, Jade Fogha, Sylvain Rault, Philippe Juin, Fabien Gautier
  • Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
    Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT
    Publication number: 20170071921
    Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.
    Type: Application
    Filed: March 3, 2015
    Publication date: March 16, 2017
    Applicants: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE, UNIVERSITE DE CAEN BASSE-NORMANDIE, INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Inventors: Laurent POULAIN, Anne-Sophie VOISIN-CHIRET, Jana SOPKOVA-DE OLIVEIRA SANTOS, Ronan BUREAU, Grégory BURZICKI, Marcella DE GIORGI, Serge PERATO, Jade FOGHA, Sylvain RAULT, Philippe JUIN, Fabien GAUTIER
  • Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
    Patent number: 9511138
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 6, 2016
    Assignees: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE REGIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE MONTPELLIER 1
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
    Publication number: 20130237584
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 12, 2013
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • Imidazol[1,2-?]quinoxalines and derivatives for the treatment of cancers
    Patent number: 8378098
    Abstract: Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 19, 2013
    Assignees: Universite de Montpellier I, American University of Beirut, Centre Regional de Lutte Contre le Cancer de Montpellier
    Inventors: Carine Deleuze-Masquefa, Georges Moarbess, Pierre-Antoine Bonnet, Frédéric Pinguet, Ali Bazarbachi, Françoise Bressolle
  • Cancer therapy using Bcl-X-specific siNA
    Patent number: 8193333
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: June 5, 2012
    Assignee: Centre Regional de Lutte Contre le Cancer-Centre Francois Baclesse
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • Human anti-idiotypic antibody fragments that mimic HER-2/neu
    Patent number: 7892542
    Abstract: This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: February 22, 2011
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Regional de Lutte Contre le Cancer “Val d'Aurelle-Paul Lamarque”, Universite Montpellier I
    Inventors: Philippe Gauthier, André Pelegrin, Mickaël Coelho, Isabelle Teulon
  • CANCER THERAPY USING BCL-XL-SPECIFIC SINA
    Publication number: 20090312393
    Abstract: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
    Type: Application
    Filed: June 22, 2007
    Publication date: December 17, 2009
    Applicant: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER - CENTRE FRANCOIS BACLESSE
    Inventors: Laurent Poulain, Pascal Gauduchon, Emilie Brotin, Ester Saison-Behmoaras
  • Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium
    Publication number: 20050148661
    Abstract: The invention relates to products comprising calcium, injectable magnesium and an injectable product which releases oxalate during the metabolism thereof as a combination that can be used for simultaneous, sequential or separate administration in anticancer and antiviral therapies.
    Type: Application
    Filed: January 14, 2003
    Publication date: July 7, 2005
    Applicant: Centre Regional de Lutte Contre le Cancer
    Inventors: Laurence Gamelin, Erick Gamelin, Michele Boisdron-Celle, Alain Morel